European CHMP recommends license extension of cabozantinib (Cabometyx) as first-line treatment for advanced renal cell carcinoma

The proposed license extension is as monotherapy for the treatment of advanced renal cell carcinoma (RCC) and in combination with nivolumab for the first-line treatment of advanced RCC in adults.

Source:

European Medicines Agency